Skip to main content

Advertisement

Table 1 Baseline clinical and demographic characteristics

From: A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center study

  Cohort (38 patients)
Gender (male/female) 9/29
Age (y), mean ± SD (range) 39.6 ± 7.3 (26–53)
Disease duration (y), mean ± SD (range) 12.0 ± 7.1 (2–31)
EDSS score, median (range) 2.0 (0–6)
Previous ARR (1y/2y before), mean ± SD 1.2 ± 0.5/0.8 ± 0.4
Previous use of ISs (yes/no) 6/32
Type of ISs (MTX/CTX) 5/1
Time from ISs suspension (y), mean ± SD (range) 7.2 ± 2.1 (4–10)
Previous use of DMDs (yes/no) 35/3
Type of DMDs (IFNs/GA/both) 17/5/13
DMDs therapy duration (y), mean ± SD (range) 5.3 ± 3.9 (0.6–15)
  1. Legend: y year, SD standard deviation, ARR annual relapse rate, ISs immunosuppressants, MTX mitoxantrone, CTX cyclophosphamide, DMDs first-line disease modyfing drugs, IFNs interferons, GA glatiramer acetate, m months, FTY fingolimod